![]() |
Volumn 56, Issue 10, 2010, Pages 560-562
|
Group prophylaxis is the best strategy
a
a
NONE
|
Author keywords
[No Author keywords available]
|
Indexed keywords
FIBRINOLYTIC AGENT;
LOW MOLECULAR WEIGHT HEPARIN;
PLACEBO;
ANTICOAGULANT AGENT;
ARTICLE;
BLEEDING;
CLINICAL TRIAL;
COST EFFECTIVENESS ANALYSIS;
DEEP VEIN THROMBOSIS;
DRUG EFFICACY;
DRUG SAFETY;
FATALITY;
HUMAN;
LUNG EMBOLISM;
PRACTICE GUIDELINE;
RETROSPECTIVE STUDY;
RISK ASSESSMENT;
RISK FACTOR;
THROMBOSIS PREVENTION;
TOTAL HIP PROSTHESIS;
TREATMENT DURATION;
VENOUS THROMBOEMBOLISM;
POSTOPERATIVE COMPLICATIONS;
PROCEDURES;
PULMONARY EMBOLISM;
VENOUS THROMBOSIS;
ANTICOAGULANTS;
HUMANS;
POSTOPERATIVE COMPLICATIONS;
PULMONARY EMBOLISM;
RISK ASSESSMENT;
RISK FACTORS;
VENOUS THROMBOEMBOLISM;
VENOUS THROMBOSIS;
|
EID: 77958193068
PISSN: 00115029
EISSN: None
Source Type: Journal
DOI: 10.1016/j.disamonth.2010.06.004 Document Type: Article |
Times cited : (1)
|
References (6)
|